58 results on '"Cisplatin/gemcitabine"'
Search Results
2. Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials
Catalog
Books, media, physical & digital resources
3. Gemcitabine, Cisplatin, and nab-Paclitaxel for Patients With Advanced Biliary Tract Cancer: Closing the GAP
4. Safety and efficacy of perioperative cisplatin/gemcitabine (cis/gem) and durvalumab (durva) for operable muscle-invasive urothelial carcinoma (MIUC): SAKK 06/17
5. Neoadjuvant nivolumab (N) plus cisplatin (C)/pemetrexed (P) or cisplatin /gemcitabine (G) in resectable NSCLC
6. Cisplatin-Gemcitabine Related Cardiomyopathy in Non-Small Cell Lung Cancer NSCLC Patient: A Case Study
7. P3.17-22 Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable NSCLC
8. 175P A prospective, randomized, double-blind study of pre-chemotherapy hydration with or without mannitol to prevent renal toxicity in non-small cell lung cancer (NSCLC) patients receiving cisplatin-gemcitabine chemotherapy
9. ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy
10. Age Has No Significant Impact on Overall Survival and on Treatment Tolerability in Relapsed Stage IV Cutaneous Malignant Melanoma Patients Receiving Cisplatin, Gemcitabine, and Treosulfan
11. HALO 110-101: Phase Ib study of PEGPH20 in combination with cisplatin + gemcitabine (PEGCISGEM) or atezolizumab (ATEZO) + CIS + GEM (PEGCISGEMATEZO) in patients with locally advanced/metastatic cholangiocarcinoma and gallbladder cancer
12. Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA)
13. Selumetinib (Sel) and cisplatin/gemcitabine (CisGem) for advanced biliary tract cancer (BTC): A randomized trial
14. Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC
15. Cerebral infarction after cisplatin-gemcitabine chemotherapy: Probable cause–effect
16. NSCLC
17. Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma
18. Re: A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results
19. Re: A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update
20. 925 STAT1 inhibition restored chemotherapy sensitivity in cisplatin/gemcitabine resistant bladder cancer
21. 22 Second-line combination chemotherapy with cisplatin, gemcitabine and paclitaxel for the treatment of advanced germ cell tumours
22. Cost-Utility Analysis of Maintenance Therapy with Either Gemcitabine or Erlotinib versus Observation with Predefined Second-Line Treatment after Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Nsclc: Ifct-Gfpc 0502-ECO Phase III Study
23. Commentary on 'Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04–75.' Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, Johnson CS, Perkins SM, Waddell MJ, Sweeney CJ; Hoosier Oncology Group, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
24. Re: Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab as First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75
25. GEFCAPI 04: A phase III trial comparing a treatment oriented by a molecular analysis with CancerTYPE ID test to cisplatin-gemcitabine in patients with carcinoma of an unknown primary (CUP)
26. ABC-04: A phase 1b trial of cisplatin, gemcitabine, and selumetinib in patients with advanced biliary tract cancer
27. ABC-03: A randomized phase II trial of cediranib (AZD2171) or placebo in combination with cisplatin/gemcitabine (CisGem) chemotherapy for patients (pts) with advanced biliary tract cancer (ABC)
28. P-457 Docetaxel/gemcitabine vs. cisplatin/gemcitabine followed bydocetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): Results of a randomised phase II trial
29. Cisplatin, gemcitabine, and vinorelbine (PGV) compared with cisplatin and etoposide (PE) in the first-line treatment of extensive-stage small-cell lung cancer: Two Brazilian institution experience
30. O-279 A multicenter randomised phase II study of cisplatin, etoposide, gemcitabine (PEG) versus cisplatin, gemcitabine (PG) as first line treatment in patients with small cell lung cancer (SCLC): Preliminary results
31. Neoadjuvant cisplatin/gemcitabine chemotherapy for muscle invasive bladder carcinoma: A single institution experience
32. 7138 POSTER High Rate of Complete Remission (CR) Using Two Sequential, Dose-dense Regimens of Cisplatin, Gemcitabine, and Paclitaxel (CGP) Followed by HD-MVAC in Patients With Metastatic Bladder Cancer (mBC)
33. 85 Mechanisms underlying the therapeutic benefit of necitumumab (IMC-11F8) in combination with cisplatin/gemcitabine in NSCLC xenograft models
34. 9172 Analysis of biomarkers (BMs) in the AVAiL phase III randomised study of first-line Bevacizumab (Bv) with cisplatin-gemcitabine (CG) in patients (pts) with non-small cell lung cancer (NSCLC)
35. Final safety results of BO17704 (AVAiL): A phase III randomized study of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in patients (pts) with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC)
36. Efficacy and safety of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) in the BO17704 study (AVAiL)
37. Use of multidrug-resistance gene (MDR1) expression levels to predict outcome to adjuvant cisplatin/gemcitabine based chemotherapy in patients with with locally advanced urothelial cancer
38. Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomised phase III trial
39. MP-04.05: Development and DNA microarray analysis of cisplatin, gemcitabine and docetaxel-resistant bladder cancer cell lines
40. A phase II study of cisplatin-gemcitabine in locally advanced and metastatic non-small cell lung cancer
41. A randomized, phase II trial comparing sequential paclitaxel/cisplatin/gemcitabine/vinorelbine/ (PCGV) with cisplatin/gemcitabine/vinorelbine/ (CGV) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
42. P-463 Preliminary results of a multicenter randomized phase II trial oftwo different combinations of docetaxel (D) and gemcitabine (G) and of cisplatin/gemcitabine (CG) followed by docetaxel as first line therapy for locally advanced or metastatic non small cell lung cancer (NSCLC)
43. O-096 Phase III study in patients with stage IV non small-cell lungcancer (NSCLC) treated with two cycles of cisplatin/gemcitabine followed by a randomization to three additional cycles of the same combination or gemcitabine alone
44. Preliminary cytogenetic and pharmacogenomic analysis of muscle-invasive transitional-cell carcinoma (TCC) of the bladder in patients (pts) enrolled in the Italian National Research Council (CNR) phase III randomized trial comparing adjuvant cisplatin-gemcitabine (PG) vs observation (OBS) after radical cystectomy
45. Phase III study in stage IV non-small-cell lung cancer (NSCLC) patients (pts) treated with two cycles of cisplatin/gemcitabine followed by a randomization to three additional cycles of the same combination or gemcitabine alone
46. Preliminary results of a multicenter randomized phase II trial of two different combinations of docetaxel (D) and gemcitabine (G) and of cisplatin/gemcitabine (CG) followed by docetaxel as first line therapy for locally advanced or metastatic non small cell lung cancer (NSCLC)
47. Sequential cisplatin–gemcitabine–docetaxel vs docetaxel–gemcitabine in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): Interim results of an ongoing phase II trial
48. A cisplatin-gemcitabine-vinorelbine (PVG) first-line treatment in IIIB-IV non small cell lung cancer (NSCLC)
49. O-26 Thalidomide alone or in combination with cisplatin/Gemcitabine in malignant pleural mesothelioma (MM); Interim results from two parallel non randomized phase II studies
50. O-52 ECOG 1599: Randomized phase II study of paclitaxel/carboplatin vs cisplatin/gemcitabine in performance status (PS) 2 patients with treatment-naive advanced NSCLC
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.